Efficacy of linezolid on gram-positive bacterial infection in elderly patients and the risk factors associated with thrombocytopenia

被引:18
|
作者
Bi, Li-qing [1 ]
Zhou, Jing [1 ]
Huang, Ming [1 ]
Zhou, Su-ming [1 ]
机构
[1] Nanjing Med Univ, Affiliated Hosp 1, Dept Geriatr Intens Care Unit, Nanjing 210029, Jiangsu, Peoples R China
关键词
Elderly; Gram-positive bacterial infections; Linezolid; Thrombocytopenia; RESISTANT STAPHYLOCOCCUS-AUREUS; IN-VITRO ACTIVITY; EXPERIENCE; OUTCOMES; SAFETY; SERIES;
D O I
10.12669/pjms.293.2925
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Linezolid is active against drug-resistant gram-positive bacteria. However, the efficacy and safety of linezolid in the treatment of the elderly have not been well characterized. The purpose of this study was to evaluate the efficacy of linezolid in the treatment of the elderly with gram-positive bacterial infection and to investigate the risk factors associated with the development of thrombocytopenia in these patients. Methodology: This was a retrospective analysis of 50 elderly patients who were treated with intravenous linezolid for gram-positive bacterial infection. Clinical data and bacteriological responses were assessed. Risk factors associated with thrombocytopenia in elderly patients were analyzed. Results: The overall clinical cure rate of linezolid was 74%, and the bacteriological eradication rate was 69%. Thrombocytopenia occurred in 24 patients, and thrombocytopenia was associated with both the duration of treatment (P = 0.005) and the baseline platelet count (P = 0.042). Based on a logistic regression analysis, the baseline platelet count < 200x10(9)/L (OR = 0.244; 95% CI = 0.068- 0.874; P = 0.030) was identified as the only significant risk factor for linezolid-associated thrombocytopenia in elderly patients. The mean platelet count decreased significantly from the 7th day of treatment, and decreased to the lowest value 1-2 days after the end of therapy. Conclusions: Linezolid is effective and safe for the elderly with gram-positive bacterial infections. Adverse effects such as thrombocytopenia are of greater concern. Platelet counts should be monitored in patients who are treated with linezolid and that measures should be taken in advance to avoid hemorrhagic tendencies.
引用
收藏
页码:837 / 842
页数:6
相关论文
共 50 条
  • [31] INCIDENCE AND RISK FACTORS FOR LINEZOLID-ASSOCIATED THROMBOCYTOPENIA IN CRITICALLY ILL PATIENTS
    Rabon, Alyssa
    Fisher, Jon
    Mazur, Joseph
    MacVane, Shawn
    CRITICAL CARE MEDICINE, 2018, 46 (01) : 319 - 319
  • [32] Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy
    Takahashi, Yoshiko
    Takesue, Yoshio
    Nakajima, Kazuhiko
    Ichiki, Kaoru
    Tsuchida, Toshie
    Tatsumi, Sumiyo
    Ishihara, Mika
    Ikeuchi, Hiroki
    Uchino, Motoi
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2011, 17 (03) : 382 - 387
  • [33] Linezolid in late-chronic prosthetic joint infection caused by gram-positive bacteria
    Cobo, Javier
    Lora-Tamayo, Jaime
    Euba, Gorane
    Jover-Saenz, Alfredo
    Palomino, Julian
    Dolores del Toro, Ma
    Rodriguez-Pardo, Dolors
    Riera, Melchor
    Ariza, Javier
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2013, 76 (01) : 93 - 98
  • [34] Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections
    MacGowan, AP
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 : 17 - 25
  • [35] Predictive Factors of Spontaneous Bacterial Peritonitis Caused by Gram-Positive Bacteria in Patients With Cirrhosis
    Kim, Jung Ho
    Jeon, Yong Duk
    Jung, In Young
    Ahn, Mi Young
    Ahn, Hea Won
    Ahn, Jin Young
    Ku, Nam Su
    Han, Sang Hoon
    Choi, Jun Yong
    Ahn, Sang Hoon
    Song, Young Goo
    Han, Kwang Hyub
    Kim, June Myung
    MEDICINE, 2016, 95 (17)
  • [36] In vitro activity of linezolid against Gram-positive isolates causing infection in continuous ambulatory peritoneal dialysis patients
    Bowker, KE
    Wootton, M
    Holt, HA
    MacGowan, AP
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 49 (03) : 578 - 580
  • [37] Correction of thrombocytopenia caused by linezolid with scheduled sequential tedizolid use in patients with vertebral osteomyelitis by antibiotic resistant Gram-positive organisms
    Ueda, Takashi
    Nakajima, Kazuhiko
    Ichiki, Kaoru
    Ishikawa, Kaori
    Yamada, Kumiko
    Tsuchida, Toshie
    Otani, Naruhito
    Takahashi, Yoshiko
    Ishihara, Mika
    Takubo, Shingo
    Iijima, Kosuke
    Ikeuchi, Hiroki
    Uchino, Motoi
    Kimura, Takeshi
    Takesue, Yoshio
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2022, 28 (07) : 1023 - 1028
  • [38] Risk factors for resistant gram-positive bacteremia in febrile neutropenic patients with cancer
    Lee, Minkyeong
    Lee, Chan Mi
    Byun, Ja min
    Shin, Dong-Yeop
    Koh, Youngil
    Hong, Junshik
    Choe, Pyoeng Gyun
    Park, Wan Beom
    Kim, Nam Joong
    Yoon, Sung-Soo
    Oh, Myoung-don
    Kang, Chang Kyung
    Kim, Inho
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2024, 30 (10) : 995 - 1000
  • [39] Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant Gram-positive bacterial pathogens
    Jantausch, BA
    Deville, J
    Adler, S
    Morfin, MR
    Lopez, P
    Edge-Padbury, B
    Naberhuis-Stehouwer, S
    Bruss, JB
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2003, 22 (09) : S164 - S171
  • [40] Comparative study on safety of linezolid and vancomycin in the treatment of infants and neonates for Gram-positive bacterial infections
    Shibata, Yuichi
    Yamagishi, Yuka
    Mikamo, Hiroshige
    Kato, Hideo
    Nishiyama, Naoya
    Asai, Nobuhiro
    Koizumi, Yusuke
    Matsuura, Katsuhiko
    Suematsu, Hiroyuki
    Hagihara, Mao
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2018, 24 (09) : 695 - 701